ReviewCurrent topics in behavioral neurosciences2017
Clinical Pharmacology of the Synthetic Cathinone Mephedrone.
Review in Current topics in behavioral neurosciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Pulmonary Arterial Hypertension Associated With Chronic Mephedrone Use: A Case Report.Pulmonary circulation · 2026Article
- Impact of Mephedrone on Fear Memory in Adolescent Rats: Involvement of Matrix Metalloproteinase-9 (MMP-9) and N-Methyl-D-aspartate (NMDA) Receptor.International journal of molecular sciences · 2023Article
- E-cigarettes may serve as a gateway to conventional cigarettes and other addictive drugs.Advances in drug and alcohol research · 2023Review
- Abuse Potential of Cathinones in Humans: A Systematic Review.Journal of clinical medicine · 2022Review
- Vulnerability factors for mephedrone-induced conditioned place preference in rats-the impact of sex differences, social-conditioning and stress.Psychopharmacology · 2021Article
- Acute Pharmacological Effects of Oral and Intranasal Mephedrone: An Observational Study in Humans.Pharmaceuticals (Basel, Switzerland) · 2021Article
- The clinical challenges of synthetic cathinones.British journal of clinical pharmacology · 2020Article
- Abuse potential and toxicity of the synthetic cathinones (i.e., "Bath salts").Neuroscience and biobehavioral reviews · 2020Review
- Extended Stability Evaluation of Selected Cathinones.Frontiers in chemistry · 2020Article
- Locomotor and reinforcing effects of pentedrone, pentylone and methylone in rats.Neuropharmacology · 2018Article
- Stereoselective Differences between the Reinforcing and Motivational Effects of Cathinone-Derived 4-Methylmethcathinone (Mephedrone) In Self-Administering Rats.ACS chemical neuroscience · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
4-Methyl-N-methylcathinone (mephedrone) is a popular new psychoactive substance (NPS) that is structurally related to the parent compound cathinone, the β-keto analogue of amphetamine. Mephedrone appeared on the street drug market as a substitute for 3,4-methylenedioxy-N-methylamphetamine (MDMA, ecstasy) and was subsequently banned due to the potential health risks associated with its use. Nevertheless, mephedrone continues to be widely consumed among specific populations, with unique patterns of misuse. To date, most information about the biological effects of mephedrone comes from user experiences, epidemiological data, clinical cases, toxicological findings, and animal studies, whilst there are very few data regarding its human pharmacodynamics and pharmacokinetics. This chapter reviews the available published data on patterns of mephedrone use, its acute and chronic effects, and its pharmacokinetic properties. More human research is needed to elucidate the safety, toxicity, and addiction potential of mephedrone and related NPS.
Indexed as
Identifiers
28012094What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.